Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination dental material used in pediatric dentistry for pulpotomy procedures in primary teeth. It consists of a non-eugenol-based zinc oxide (ZOE) base material applied over pulp tissue that has been treated with ferric sulfate. Ferric sulfate acts as a hemostatic agent to control bleeding and provides antimicrobial effects, while the non-eugenol ZOE serves as a protective base or liner over the pulp. The use of a non-eugenol formulation aims to avoid the inflammatory response and internal resorption associated with eugenol-containing materials. This combination is primarily indicated for vital pulp therapy (pulpotomy) in primary molars affected by caries but without evidence of root pathology[1][2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on non-eugenol zinc oxide + ferric sulfate.